BIOCON'S SYNGENE CLAIMS OF DEVELOPING NEW COVID TECHNOLOGY

Highlights

• Syngene is ready with the technology and will soon send it to the National Institute of Biologicals (NIB) in order to get an approval

• According to executive chairperson Kiran Mazumdar-Shaw, the cost of a test will not exceed Rs 250

• Biocon is also working on rerepurposing its drug Itolizumab to treat coronavirus complications

India’s leading techno company Biocon'....